Summit Therapeutics
Most recent annual filing: 2026-02-15
- ivonescimab + GSK B7-H3 ADCMid-2026ivonescimab + GSK B7-H3 ADC, Mid-2026, routine
- ivonescimab NSCLC interim2H 2026ivonescimab NSCLC interim, 2H 2026, material
- HARMONi-GU1 corporate update4Q 2026HARMONi-GU1 corporate update, 4Q 2026, routine
- ivonescimab NSCLC PDUFA dateNov 14, 2026ivonescimab NSCLC PDUFA date, Nov 14, 2026, thesis-defining
- ivonescimab NSCLC FDA decisionNov 14, 2026ivonescimab NSCLC FDA decision, Nov 14, 2026, thesis-defining
- HARMONi-3 non-squamous readout1H 2027HARMONi-3 non-squamous readout, 1H 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
ivonescimab
SMT112Discontinued (1)
- ivonescimab — Clear Cell Renal Cell Carcinoma · not a Summit-sponsored program — Arcus conducts and sponsors the casdatifan+ivonescimab ccRCC cohort in its ARC-20 platform study; Summit only supplies drug and co-funds (collaborator, not sponsor)
Biotech Distilled coverage (12)
- 2026-08-13 UPDATE: Summit Therapeutics (SMMT) - China Says Yes, Round Three 🔒 Paid
- 2026-07-23 UPDATE: Summit Therapeutics (SMMT) - The Form 4s Landed 🔒 Paid
- 2026-07-22 UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up 🔒 Paid
- 2026-06-11 UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled
- 2026-06-09 UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch
- 2026-06-03 UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light
- 2026-06-02 UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn’t. 🔒 Paid
- 2026-05-02 UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 🔒 Paid
- 2026-05-01 UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot 🔒 Paid
- 2026-03-29 UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data 🔒 Paid
- 2026-03-01 UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update 🔒 Paid
- 2026-02-20 Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.